Cargando…

How do we identify people at high risk of Type 2 diabetes and help prevent the condition from developing?

AIMS: To review the evidence regarding the identification of those at high risk of Type 2 diabetes and the conceptual and clinical criteria defining high risk, the prevention or delay of onset of Type 2 diabetes through lifestyle interventions, and the evolution of evidence from efficacy trials, thr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fagg, J., Valabhji, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Invited Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590463/ https://www.ncbi.nlm.nih.gov/pubmed/30466172 http://dx.doi.org/10.1111/dme.13867

Ejemplares similares

Injury prevention, performance and return to sport: How can science help?
por: McGregor, Alison H.
Publicado: (2017)

Genome-forward oncology: how do we get there?
por: Ellis, Matthew
Publicado: (2011)

Do we really need another risk prediction rule? Yes, we do
por: Lo, Alexander X., et al.
Publicado: (2022)

Poor Clinician Adherence to Inflammatory Bowel Disease Guidelines: How Do We Remedy the Situation?
por: Hart, Lara, et al.
Publicado: (2022)

Do We Have the Spark?
por: Rupel, Valentina Prevolnik, et al.
Publicado: (2022)

What Do We Know About Depression Among Youth and How Can We Make Progress Toward Improved Understanding and Reducing Distress? A New Hope
por: Hankin, Benjamin L., et al.
Publicado: (2023)

How do I diagnose Maturity Onset Diabetes of the Young in my patients?
por: Colclough, Kevin, et al.
Publicado: (2022)

Lycopene and male infertility: do we know enough?
por: Pakrashi, Tarita, et al.
Publicado: (2014)

Predicting the outcome of normal pressure hydrocephalus therapy—where do we stand?
por: Oertel, Joachim M. K., et al.
Publicado: (2021)

The preventive treatment of recurrent stone-formation: how can we improve compliance in the treatment of patients with recurrent stone disease?
por: Kok, Dirk Jan
Publicado: (2015)

Editorial: gut microbial profile associated with primary sclerosing cholangitis—what is new and how do we progress from here? Authors’ reply
por: Rühlemann, Malte, et al.
Publicado: (2019)

Prevention of cardiovascular disease: are we successful?( )
por: De Backer, Guy
Publicado: (2022)

Transfer-consultations for young people: how do we do?
por: Teilmann, G, et al.
Publicado: (2011)

Dual use of antifungals in medicine and agriculture: How do we help prevent resistance developing in human pathogens?
por: Verweij, Paul E., et al.
Publicado: (2022)

Pharmacological plasticity—How do you hit a moving target?
por: Parnham, Michael J., et al.
Publicado: (2019)

How can and should we optimize extracorporeal shockwave lithotripsy?
por: Chaussy, Christian G., et al.
Publicado: (2017)

Clinical studies in the elderly – Why and how should we care?
por: Sousa, Nuno
Publicado: (2021)

Recurring Cystitis: How Can We Do Our Best to Help Patients Help Themselves?
por: Ben Hadj Messaoud, Sarah, et al.
Publicado: (2022)

Do we always need anticoagulation before cardioversion of atrial fibrillation in ladies?
por: Görenek, Bülent, et al.
Publicado: (2016)

Invited Perspective: Oil and Gas Development and Adverse Birth Outcomes: What More Do We Need to Know?
por: Deziel, Nicole C.
Publicado: (2021)

How many skin barriers haveth we: Percutaneous egression of ions?
por: Chiang, Chavy, et al.
Publicado: (2021)

Do we need to demonstrate Amyloid in tissue?
por: Magy, Laurent
Publicado: (2015)

How do psychological treatments work? Investigating mediators of change
por: Murphy, Rebecca, et al.
Publicado: (2009)

Genetic hearing loss: the journey of discovery to destination – how close are we to therapy?
por: Pandya, Arti
Publicado: (2016)

Multisystem inflammatory syndrome in children and complete atrioventricular block: What have we learned so far and where do we go from here?
por: Clark, Bradley C, et al.
Publicado: (2021)

Animal Mitochondrial DNA as We Do Not Know It: mt-Genome Organization and Evolution in Nonbilaterian Lineages
por: Lavrov, Dennis V., et al.
Publicado: (2016)

Future collapse: how optimistic should we be?
por: Ehrlich, Paul R., et al.
Publicado: (2013)

The postictal state — What do we know?
por: Pottkämper, Julia C. M., et al.
Publicado: (2020)

How do we prevent scientific fraud?
por: Spires-Jones, Tara L
Publicado: (2022)

Preventing treatment delays for benign gynaecological conditions
por: Robinson, Dudley
Publicado: (2022)

What do the “new” Pulmonary Hypertension Guidelines tell us: should we change our practice?
por: Kaymaz, Cihangir, et al.
Publicado: (2016)

The Unfulfilled Promise of Inhaled Therapy in Ventilator-Associated Infections: Where Do We Go from Here?
por: Palmer, Lucy B., et al.
Publicado: (2022)

Malaria: How Are We Doing and How Can We Do Better?
por: Rosenthal, Philip J., et al.
Publicado: (2019)

Effect of the COVID-19 pandemic on body weight in people at high risk of type 2 diabetes referred to the English NHS Diabetes Prevention Programme
por: Valabhji, Jonathan, et al.
Publicado: (2021)

Extended lymph node dissection for intermediate and high-risk prostate cancer: do we have all the evidence?
por: Ghazi, Ahmed
Publicado: (2015)

How do psychiatrists in India construct their professional identity? A critical literature review
por: Bayetti, Clement, et al.
Publicado: (2017)

How can we cure a heart “in flame”? A translational view on inflammation in heart failure
por: Hofmann, Ulrich, et al.
Publicado: (2013)

Do we need to demonstrate amyloid in tissue for hereditary ATTR amyloidosis ?
por: Westermark, Per
Publicado: (2015)

Who Cares for People With Diabetes? We Do!
por: Brunton, Stephen
Publicado: (2017)

How Do We Define Cure of Diabetes?
por: Buse, John B., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_c2atj9jn09ckupjivt2hd43rhm